We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metformin in Assisted Reproduction-MET-AR-study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00159575
Recruitment Status : Terminated (Slow patient recruitment and expiry of study medication(aug2009))
First Posted : September 12, 2005
Last Update Posted : January 5, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Aim of study: To investigate whether four months of metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic-sperm-injection) might increase clinical pregnancy rate in normal-weight (body mass index [BMI] below 28 kg/m3) in PCOS (polycystic ovarian syndrome) women.

Condition or disease Intervention/treatment Phase
Polycystic Ovary Syndrome Drug: Metformin / Placebo treatment for 4 months Phase 4

Detailed Description:

PCOS is an hormonal disease including hyperandrogenism, oligo-or anovulation and/or polycystic ovaries by ultrasound. PCOS women often suffer insulin resistance or even diabetes risk as well as a full blown metabolic disease.

These women often suffer infertility due to their lack of regular ovulations. Metformin is a well known anti-diabetic drug, and in some PCOS women metformin might decrease the hyperandrogenism, improve insulin resistance and give more regular ovulations. Thereby increase chance of pregnancy. Our hypothesis is that metformin will increase clinical pregnancy rates both spontaneously and following IVF/ICSI.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome
Study Start Date : March 2005
Primary Completion Date : August 2009
Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: M: Metformin P: Placebo Drug: Metformin / Placebo treatment for 4 months
M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period


Outcome Measures

Primary Outcome Measures :
  1. To investigate whether four months of Metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic sperm injection) will increase clinical pregnancy rate in normal weight PCOS-women [ Time Frame: Vaginal ultrasound in pregnancy week 7 ]

Secondary Outcome Measures :
  1. Spontaneous pregnancy rates during the pretreatment period, Spontaneous abortion rates (I or II trim.abortions), Live birth rates, [ Time Frame: Vaginal ultrasound in pregnancy week 7 ]
  2. Number of oocytes collected, Embryo quality, Number of days of gonadotrophin treatment, Dose of gonadotrophin, total per cycle and daily, s-estradiol on day of hCG-administration, Occurrence of ovarian hyperstimulation syndrome (OHSS) [ Time Frame: All data evaluated at study end, from september 2009 onwards ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Fulfilling Rotterdam criteria for PCOS
  • Infertility more than 1 year
  • First or second cycle of IVF/ICSI treatment
  • Age below 38 years at inclusion
  • BMI below 28 kg/m3 at inclusion
  • Willing to be randomised to 4 months metformin or placebo
  • Signed written informed consent

Exclusion Criteria:

  • Not suitable for starting dose 112.5 IE
  • Basal FSH above 10 IU/L
  • Known renal disease or s-creatinine above 110 umol/L
  • Known liver disease or s-ALAT above 80 IU/L
  • Known alcoholism or drug abuse
  • Known diabetes mellitus or fasting plasma glucose above 7 mmol/L
  • Corticosteroid treatment (oral)
  • Treatment with cimetidine, anticoagulants, erythromycin or other macrolides
  • Hyperprolactinemia (PRL above 700 mIU/L)
  • Abnormal thyroid function tests
  • Known congenital adrenal hyperplasia
  • Androgen secreting tumours
  • Cushing syndrome
  • Metformin treatment within the last one month prior to screening
  • Unfit to participate for any other reason
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159575


Locations
Norway
Sigrun Kjøtrød
Trondheim, Norway, 7006
Fertility UNit- -St Olavs Hospital
Trondheim, Norway, 7046
Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Study Chair: Sven Carlsen, MD,PhD St Olavs Hospital- Endocrinological section
More Information

Publications:
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00159575     History of Changes
Other Study ID Numbers: MET-AR study -PCOS 5
EUDRACTNR. 2004-001124-20
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: January 5, 2012
Last Verified: January 2012

Keywords provided by Norwegian University of Science and Technology:
Polycystic ovarian syndrome
Clinical pregnancy rate
Oligo- or anovulation

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Syndrome
Disease
Pathologic Processes
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs